Format
Items per page
Sort by

Send to:

Choose Destination

Results: 20

1.

Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.

Lip GY, Larsen TB, Skjøth F, Rasmussen LH.

J Am Coll Cardiol. 2012 Aug 21;60(8):738-46. doi: 10.1016/j.jacc.2012.03.019. Epub 2012 May 9.

3.

Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada. Comparative efficacy and cost-effectiveness.

Kansal AR, Sharma M, Bradley-Kennedy C, Clemens A, Monz BU, Peng S, Roskell N, Sorensen SV.

Thromb Haemost. 2012 Oct;108(4):672-82. Epub 2012 Aug 17.

PMID:
22898892
4.

Primary and secondary prevention with new oral anticoagulant drugs for stroke prevention in atrial fibrillation: indirect comparison analysis.

Rasmussen LH, Larsen TB, Graungaard T, Skjøth F, Lip GY.

BMJ. 2012 Nov 5;345:e7097. doi: 10.1136/bmj.e7097.

5.

Stroke Prevention in Atrial Fibrillation Study. Final results.

[No authors listed]

Circulation. 1991 Aug;84(2):527-39.

PMID:
1860198
6.

Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.

Potpara TS, Polovina MM, Licina MM, Stojanovic RM, Prostran MS, Lip GY.

Adv Ther. 2012 Jun;29(6):491-507. doi: 10.1007/s12325-012-0026-8. Epub 2012 Jun 7. Review.

PMID:
22684583
7.

Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control.

Skanes AC, Healey JS, Cairns JA, Dorian P, Gillis AM, McMurtry MS, Mitchell LB, Verma A, Nattel S; Canadian Cardiovascular Society Atrial Fibrillation Guidelines Committee.

Can J Cardiol. 2012 Mar-Apr;28(2):125-36. doi: 10.1016/j.cjca.2012.01.021. Erratum in: Can J Cardiol. 2012 May;28(3):396.

PMID:
22433576
9.

Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial.

Mant J, Hobbs FD, Fletcher K, Roalfe A, Fitzmaurice D, Lip GY, Murray E; BAFTA investigators; Midland Research Practices Network (MidReC).

Lancet. 2007 Aug 11;370(9586):493-503.

PMID:
17693178
10.

Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation.

Lee S, Anglade MW, Pham D, Pisacane R, Kluger J, Coleman CI.

Am J Cardiol. 2012 Sep 15;110(6):845-51. doi: 10.1016/j.amjcard.2012.05.011. Epub 2012 May 30.

PMID:
22651881
11.

Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation.

Kansal AR, Sorensen SV, Gani R, Robinson P, Pan F, Plumb JM, Cowie MR.

Heart. 2012 Apr;98(7):573-8. doi: 10.1136/heartjnl-2011-300646.

12.

Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial.

Wallentin L, Yusuf S, Ezekowitz MD, Alings M, Flather M, Franzosi MG, Pais P, Dans A, Eikelboom J, Oldgren J, Pogue J, Reilly PA, Yang S, Connolly SJ; RE-LY investigators.

Lancet. 2010 Sep 18;376(9745):975-83. doi: 10.1016/S0140-6736(10)61194-4.

PMID:
20801496
13.

Stroke prevention in atrial fibrillation: understanding the new oral anticoagulants dabigatran, rivaroxaban, and apixaban.

Ru San T, Chan MY, Wee Siong T, Kok Foo T, Kheng Siang N, Lee SH, Chi Keong C.

Thrombosis. 2012;2012:108983. Epub 2012 Sep 10.

14.

Current trial-associated outcomes with warfarin in prevention of stroke in patients with nonvalvular atrial fibrillation: a meta-analysis.

Agarwal S, Hachamovitch R, Menon V.

Arch Intern Med. 2012 Apr 23;172(8):623-31; discussion 631-3. doi: 10.1001/archinternmed.2012.121. Epub 2012 Mar 26. Review.

PMID:
22450212
15.

Prevention of stroke in patients with atrial fibrillation.

Olsson SB, Halperin JL.

Semin Vasc Med. 2005 Aug;5(3):285-92. Review.

PMID:
16123916
16.

Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment.

Fox KA, Piccini JP, Wojdyla D, Becker RC, Halperin JL, Nessel CC, Paolini JF, Hankey GJ, Mahaffey KW, Patel MR, Singer DE, Califf RM.

Eur Heart J. 2011 Oct;32(19):2387-94. doi: 10.1093/eurheartj/ehr342. Epub 2011 Aug 28.

17.

Antithrombotic therapy for stroke prevention in non-valvular atrial fibrillation.

Alberts MJ, Eikelboom JW, Hankey GJ.

Lancet Neurol. 2012 Dec;11(12):1066-81. doi: 10.1016/S1474-4422(12)70258-2. Review.

PMID:
23153406
18.

Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation.

Freeman JV, Zhu RP, Owens DK, Garber AM, Hutton DW, Go AS, Wang PJ, Turakhia MP.

Ann Intern Med. 2011 Jan 4;154(1):1-11. doi: 10.7326/0003-4819-154-1-201101040-00289. Epub 2010 Nov 1.

PMID:
21041570
20.

Cost-effectiveness of apixaban vs warfarin for secondary stroke prevention in atrial fibrillation.

Kamel H, Easton JD, Johnston SC, Kim AS.

Neurology. 2012 Oct 2;79(14):1428-34. doi: 10.1212/WNL.0b013e31826d5fe8. Epub 2012 Sep 19.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk